person · Reporting owner
CEDARS SINAI MEDICAL CENTER
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CAPRICOR THERAPEUTICS, INC.CAPR · Entity 5337 | 10% owner | May 09, 2017 | May 12, 2017 |
| Prometheus Biosciences, Inc.RXDX · Entity 112175 | 10% owner | March 16, 2021 | March 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CAPRICOR THERAPEUTICS, INC.
Report date May 09, 2017 · Filed May 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,049,959 |
Reported balance
After 2017-05-09 transaction · row 1
1 source rowRow 1 · 2017-05-09 · Purchase · Acquired 1,145,161 · Balance 4,049,959 F1: The Reporting Person entered into a Subscription Agreement with Capricor Therapeutics, Inc. (the "Issuer") pursuant to which the Reporting Person, on May 5, 2017 purchased an aggregate of 1,145,161 shares of the Issuer's common stock at a purchase price of $3.10 per share for total cash proceeds of approximately US$3,550,000. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person entered into a Subscription Agreement with Capricor Therapeutics, Inc. (the "Issuer") pursuant to which the Reporting Person, on May 5, 2017 purchased an aggregate of 1,145,161 shares of the Issuer's common stock at a purchase price of $3.10 per share for total cash proceeds of approximately US$3,550,000.
Prometheus Biosciences, Inc.
Report date March 16, 2021 · Filed March 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,008,508 |
Ending reported balance
After 2021-03-16 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-03-16 · Conversion · Acquired 100,000 · Balance 692,500 F1: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Row 2 · 2021-03-16 · Conversion · Acquired 1,200,000 · Balance 1,892,500 F2: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Row 3 · 2021-03-16 · Conversion · Acquired 2,500,000 · Balance 4,392,500 F3: The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Row 4 · 2021-03-16 · Conversion · Acquired 254,442 · Balance 4,646,942 F4: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Row 5 · 2021-03-16 · Conversion · Acquired 361,566 · Balance 5,008,508 F5: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-03-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-16 · Conversion · Disposed 1,000,000 · Balance 0 F1: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-03-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-03-16 · Conversion · Disposed 12,000,000 · Balance 0 F2: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-03-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-03-16 · Conversion · Disposed 25,000,000 · Balance 0 F3: The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. |
| Series D-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-03-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-03-16 · Conversion · Disposed 2,544,425 · Balance 0 F4: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. |
| Series D-2 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-03-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-03-16 · Conversion · Disposed 3,615,656 · Balance 0 F5: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
F2: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
F3: The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
F4: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
F5: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2021 Filed Mar 16, 2021 21:53 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionSeries D-2 Preferred Stock · Derivative | 3,615,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021223 · doc4.xml · derivative · entry 10 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 361,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F5 · price: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F5 · derivative.exercise_date: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F5 · derivative.expiration_date: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:53 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionSeries D-1 Preferred Stock · Derivative | 2,544,425 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021223 · doc4.xml · derivative · entry 9 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 254,442 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F4 · price: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F4 · derivative.exercise_date: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F4 · derivative.expiration_date: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:53 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionSeries C Preferred Stock · Derivative | 25,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021223 · doc4.xml · derivative · entry 8 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F3 · price: The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F3 · derivative.exercise_date: The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F3 · derivative.expiration_date: The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:53 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionSeries B Preferred Stock · Derivative | 12,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021223 · doc4.xml · derivative · entry 7 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F2 · price: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.exercise_date: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:53 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionSeries A Preferred Stock · Derivative | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021223 · doc4.xml · derivative · entry 6 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:53 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionCommon Stock | 361,566 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021223 · doc4.xml · nonDerivative · entry 5 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,008,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:53 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionCommon Stock | 254,442 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021223 · doc4.xml · nonDerivative · entry 4 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,646,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:53 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionCommon Stock | 2,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021223 · doc4.xml · nonDerivative · entry 3 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,392,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:53 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionCommon Stock | 1,200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021223 · doc4.xml · nonDerivative · entry 2 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,892,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| March 16, 2021 Filed Mar 16, 2021 21:53 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | ConversionCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021223 · doc4.xml · nonDerivative · entry 1 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| May 09, 2017 Filed May 12, 2017 00:56 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | PurchaseCommon Stock | 1,145,161 | $3.10 | $3,549,999.10 |
DisclosureSEC source: 0001144204-17-026585 · v466675_4.xml · nonDerivative · entry 1 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,049,959 F1 · kind: The Reporting Person entered into a Subscription Agreement with Capricor Therapeutics, Inc. (the "Issuer") pursuant to which the Reporting Person, on May 5, 2017 purchased an aggregate of 1,145,161 shares of the Issuer's common stock at a purchase price of $3.10 per share for total cash proceeds of approximately US$3,550,000. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 01:10 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | PurchaseCommon Stock | 312,500 | $3.20 | $1,000,000.00 |
DisclosureSEC source: 0001144204-16-124964 · v449260_4.xml · nonDerivative · entry 1 CEDARS SINAI MEDICAL CENTER · CIK 0001269910 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,904,798 F1 · kind: The Reporting Person entered into a Subscription Agreement with Capricor Therapeutics, Inc. (the "Issuer") pursuant to which the Reporting Person, on September 21, 2015, purchased an aggregate of 312,500 shares of the Issuer's common stock at a purchase price of $3.20 per share for total cash proceeds of approximately US$1,000,000. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.